biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Chiesi

<< Previous

Bullboard Posts

Next >>

Comment by prophetoffactzon Jan 09, 2023 10:48pm

74 Views

Post# 35212587

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Chiesi

"Yes, yes, poof, and the market just doesn't understand Midatech/Biodexa as well as you do."

I had hoped for a 'Saltarelli' before the halt - a deal consistent with Saltarelli's track record of success. He's brought along Armistitce Capital and Ladenberg Thalamann corroborating that we are hot the the trail of a 'Saltarelli'. He's moving to Biodexa and says he's excited. Biodexa's lead asset for glioblastoma is already significantly de-risked given the drug has previously been approved and given results in the rare pediatric brain cancer trial already completed, etc. Q-Sphera is also de-risked. Saltarelli is excited and is in the catbird seat.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing